Medicare Dialysis Bundle And New Drugs: Will Transitional Payments Work For Korsuva, Vadadustat?
Quick provider uptake will be key for upcoming new drugs covered by the Medicare end stage renal disease prospective payment system.
You may also be interested in...
FDA Says Safety Concerns May Negate Any Oral Dosing Advantage For GSK’s Anemia Treatment
When a drug’s biggest advantage becomes its potential downfall: The agency worries that chronic kidney disease patients not receiving dialysis may have worse outcomes on GSK’s anemia treatment daprodustat compared to ESA because of less patient safety monitoring as a result of the drug’s oral administration.
CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
Keeping Track: Merck & Co. In Spotlight With Welireg, Keytruda Approvals; FibroGen/AZ Roxadustat CRL Is No Surprise
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.